<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medications</title>
	<atom:link href="https://www.worldpharmatoday.com/topics/medications/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Thu, 24 Jul 2025 05:56:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>Medications</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Pharmaceutical Stewardship in LMICs for AMR Control</title>
		<link>https://www.worldpharmatoday.com/health-wellness/pharmaceutical-stewardship-in-lmics-for-amr-control/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 16 Jul 2025 07:04:10 +0000</pubDate>
				<category><![CDATA[Health & Wellness]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Medication]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[Sustainable Development Goals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/pharmaceutical-stewardship-in-lmics-for-amr-control/</guid>

					<description><![CDATA[<p>Pharmaceutical Stewardship in LMICs: Key to Sustainable AMR Control Antimicrobial resistance (AMR) is one of the most challenging health issues of the 21st century, with the potential to undo decades of gains in medicine. Perhaps nowhere is the problem more pronounced than in low- and middle-income countries (LMICs), where there has been uncontrolled sale and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/health-wellness/pharmaceutical-stewardship-in-lmics-for-amr-control/">Pharmaceutical Stewardship in LMICs for AMR Control</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines</title>
		<link>https://www.worldpharmatoday.com/press-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 03 Jul 2025 10:40:23 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines/</guid>

					<description><![CDATA[<p>London, 28 June 2025 – In its ongoing mission to help meet America’s growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&#38;D capabilities. This new phase of investment – America Leans on Hikma: Quality Medicines Manufactured in the [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/press-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines/">Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>API China, PHARMCHINA &#038; NHNE 2025 Conclude with Global Win</title>
		<link>https://www.worldpharmatoday.com/news/api-china-pharmchina-nhne-2025-conclude-with-global-win/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 31 May 2025 04:59:24 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Health & Wellness]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<category><![CDATA[Healthcare Practitioners]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Sustainable Development Goals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/api-china-pharmchina-nhne-2025-conclude-with-global-win/</guid>

					<description><![CDATA[<p>API China, PHARMCHINA &#38; NHNE 2025 Close in Guangzhou with Thumping Success, Solidifying China as a World Pharma Leader Guangzhou, May 24, 2025 — In a strong demonstration of innovation, industrial synergy, and global cooperation, the 92nd API China, 90th PHARMCHINA, and the 2025 China International Natural Health &#38; Nutrition Expo (NHNE) closed on May [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/api-china-pharmchina-nhne-2025-conclude-with-global-win/">API China, PHARMCHINA & NHNE 2025 Conclude with Global Win</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Green Chemistry in EU Shapes Pharmaceutical Intermediates</title>
		<link>https://www.worldpharmatoday.com/biopharma/green-chemistry-in-eu-shapes-pharmaceutical-intermediates/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 24 Apr 2025 09:16:47 +0000</pubDate>
				<category><![CDATA[BioPharma]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Medication]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/green-chemistry-in-eu-shapes-pharmaceutical-intermediates/</guid>

					<description><![CDATA[<p>Green chemistry is a cutting-edge scientific discipline that focuses on developing environmentally friendly and sustainable chemical processes.  In the pharmaceutical industry, it has been gaining significant interest. Green chemistry in EU is transforming the production and usage of pharmaceutical intermediates, which are essential components of medicine manufacturing, where stringent environmental regulations and sustainability goals are [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/biopharma/green-chemistry-in-eu-shapes-pharmaceutical-intermediates/">Green Chemistry in EU Shapes Pharmaceutical Intermediates</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Specialty Chemicals Solubility Enhances Drug Formulations</title>
		<link>https://www.worldpharmatoday.com/drug-research/specialty-chemicals-solubility-enhances-drug-formulations/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 24 Apr 2025 08:23:16 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[Medication]]></category>
		<category><![CDATA[Medications]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/specialty-chemicals-solubility-enhances-drug-formulations/</guid>

					<description><![CDATA[<p>The need to improve the effectiveness, safety, and accessibility of drugs drives research and innovation in the ever-evolving pharmaceutical industry.  The problem of solubility and bioavailability, which affect how well a medication reaches its intended biological target after oral delivery, is one of the most important issues facing drug developers.  Because of their unique qualities [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/drug-research/specialty-chemicals-solubility-enhances-drug-formulations/">Specialty Chemicals Solubility Enhances Drug Formulations</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Biopharma Docs Transformed with Component-Based Approach</title>
		<link>https://www.worldpharmatoday.com/it-data-management/biopharma-docs-transformed-with-component-based-approach/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Mon, 10 Mar 2025 06:23:37 +0000</pubDate>
				<category><![CDATA[IT & Data Management]]></category>
		<category><![CDATA[Biopharmaceutical Development]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Treatments]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/biopharma-docs-transformed-with-component-based-approach/</guid>

					<description><![CDATA[<p>Simplifying Biopharma Workflows: How Component-Based Authoring Is Changing Clinical Trial and Regulatory Documentation In the biopharma sector, where accuracy, compliance, and efficiency rule, documentation is the lifeblood of activities.  From clinical trial procedures to regulatory filings and worldwide labelling, every document has to follow precise guidelines, remain consistent, and satisfy deadlines.  Still, conventional approaches of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/it-data-management/biopharma-docs-transformed-with-component-based-approach/">Biopharma Docs Transformed with Component-Based Approach</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Alexion and DHL Partner for 100% Sustainable Aviation Fuel</title>
		<link>https://www.worldpharmatoday.com/news/alexion-and-dhl-partner-for-100-sustainable-aviation-fuel/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 25 Feb 2025 08:02:14 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Medications]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Sustainable Development Goals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/alexion-and-dhl-partner-for-100-sustainable-aviation-fuel/</guid>

					<description><![CDATA[<p>Dublin, Alexion, AstraZeneca Rare Disease, has partnered with DHL Express to achieve Ireland’s first 100% switch to Sustainable Aviation Fuel (SAF) for international air delivery of medicines. This move will reduce greenhouse gas (GHG) emissions by over 80% compared to traditional aviation fuel, covering shipments to 19 European countries. SAF, provided through DHL’s GoGreen Plus [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/alexion-and-dhl-partner-for-100-sustainable-aviation-fuel/">Alexion and DHL Partner for 100% Sustainable Aviation Fuel</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
